A total of 183 hematologic malignancies with t(4;11)(q21;q23), including five variant translocations, were collected by the Workshop. Clinical, morphologic and immunophenotypic features were compiled, and karyotypes with variant t(4;11) or secondary chromosomal aberrations were reviewed. All cases were acute leukemias (AL): 173 acute lymphoblastic leukemias (ALL), six acute myeloid leukemias (AML), three unclassifiable AL, and one biphenotypic AL. Ten patients had treatment-associated AL. Females were overrepresented (104 vs 79) and the age distribution was clearly nonrandom; 34% of the cases occurred in infants below the age of 12 months. The remaining AL were evenly distributed among the other age groups, with the oldest patient being 79 years old. An increased white blood cell count (WBC) was reported in more than 90% of the cases, with hyperleukocytosis (у100 × 10 9 /l) in 64%. Additional chromosomal changes were detected in 55 (30%) cases, most often gain of the X chromosome, i(7)(q10), and trisomy 8, with frequent breakpoints in 1p36, 1q21, 7q10, 11p15, 12p13, 17p11 , and 17p10. All recurrent secondary changes resulted in genomic imbalances, in particular gains of 1q, 7q, 8, and X and losses of 7p and 17p. Event-free and overall survival (EFS and OS) could be ascertained in 170 and 171 patients, respectively. Kaplan-Meier estimates of EFS and OS showed no differences with regard to gender, WBC, or presence of secondary chromosomal abnormalities, and there was no increase of EFS or OS among the 55 cases that had undergone bone marrow transplantation. However, age had an important prognostic impact, with significantly (P Ͻ 0.0001) longer EFS and OS in children 2-9 years old than among infants and younger children, patients aged between 10 and 39 years and older adults.
Introduction
Cytogenetic investigations of hematologic malignancies have been instrumental in delineating genomic sites harboring genes that, if structurally rearranged or otherwise deregulated, are intimately associated with the neoplastic process. [1] [2] [3] One of the most common cytogenetic abnormalities seen in acute leukemias are structural rearrangements of chromosome band 11q23, with t(4;11)(q21;q23) being the most frequent. [4] [5] [6] [7] [8] Since the first descriptions of t(4;11) in acute lymphoblastic leukemia (ALL) in the latter half of the 1970s, [9] [10] [11] more than 350 cases with this translocation have been reported. 5 Recent molecular genetic investigations have revealed that abnormalities involving 11q23 often lead to rearrangement of the MLL (ALL1, HRX, HTRX1) gene [12] [13] [14] [15] [16] and that the t(4;11) results in a fusion between the MLL and the AF4 (FEL, LTG4, MLLT2) genes. [17] [18] [19] [20] [21] The identification of this chimeric transcript, which occasionally is also detected in leukemias lacking the t(4;11) cytogenetically, has provided the necessary information to establish reverse-transcriptase polymerase chain reaction assays for rapid and sensitive detection of the abnormality and for disease monitoring. [22] [23] [24] [25] [26] [27] Apart from these molecular data, much information as regards the clinical and phenotypic impact of t(4;11) has been forthcoming. Clinical hallmarks of t(4;11)-positive leukemia include young age at presentation, hyperleukocytosis, hepatosplenomegaly, relatively high frequency of CNS involvement, overrepresentation of females, and poor response to therapy. 10, 11, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] The blast cells have, by morphologic, cytochemical, ultrastructural, molecular genetic and immunologic means, been shown to display a mixture of lymphoid and myeloid features, suggesting that the cell of origin is an early progenitor with the potential for both lymphoid and myelomonocytic differentiation. Most leukemias are classified morphologically, using standard light microscopic criteria, as ALL of L1 or L2 type, although a few cases of acute myeloid leukemias (AML), mostly myelomonocytic, have been reported. 5, 31, 35, 47, 48 Support for myeloid involvement, however, stems mainly from electron microscopy, ultracytochemical and immunophenotypic findings showing myeloid, monocytic ultrastructural features and occasional positivity for myeloperoxidase and nonspecific esterase, and aberrant expression of the myeloid, monocytic antigens CD15 and CD65, as well as of the chondroitin sulfate proteoglycan molecule NG2, which is expressed in cells of some cases of AML but not by normal hematopoietic cells. 24, 32, 34, 35, 38, 41, 44, 45, [47] [48] [49] [50] [51] Furthermore, in vitro induction studies have revealed that the leukemic cells are capable of differentiation into cells with a monocyte-like phenotype after treatment with 12-O-tetradecanoyl-phorbol-13-acetate. 52, 53 Otherwise, the blasts usually display features of an early B cell leukemia with heavy-chain immunoglobulin gene rearrangement and positivity for periodic acid-Schiff staining, TdT, HLA-DR, CD34, CD19, CD9, and CD24. Expression of CD10, cytoplasmic and surface immunoglobulin, and T cell antigens, on the other hand, is only rarely reported in leukemias with t(4;11). [31] [32] [33] [34] [35] [38] [39] [40] [41] [42] [47] [48] [49] [50] 54 Despite all the information collected concerning t(4;11)-positive hematologic disorders, much remains unknown. The prevalence and prognostic significance of t(4;11) in different age groups and types of leukemia are uncertain. The incidence of secondary aberrations and their possible clinical impact have not been well studied. As part of the European 11q23 Workshop a total of 183 hematologic malignancies with t(4;11), or variants thereof, were collected, and we here present the cytogenetic, morphologic, immunophenotypic and clinical features of these cases.
Materials and methods
Detailed information regarding the period of study, participating groups, inclusion criteria, type of clinical, morphologic, cytochemical and immunophenotypic data collected, review of slides and karyograms, and statistical analyses used is given in Secker-Walker et al.
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Results
Basic clinical information and presenting features of the 183 hematologic malignancies with t(4;11)(q21;q23), or variant translocations, are given in Table 1 . All cases were acute leukemias (AL), the vast majority ALL (95%); six were AML, four of which were myelomonocytic/monoblastic ( Figure 1 ). Ten (5.5%) patients had treatment-associated AL. The age distribution was clearly nonrandom, with 34% of cases of AL occurring in infants below the age of 12 months. The remain- ing cases were quite evenly distributed among the other age groups, with the oldest patient being 79 years old. In the sample as a whole there were more females than males (104 vs 79). This skewed sex distribution was seen in infants and in adults (у15 years) and was particularly marked under the age of 6 months and over the age of 40 years. In contrast, amongst children aged 1 to 14 years there were more boys (21 patients) than girls (15 patients). An increased WBC (у10 × 10 9 /l) was detected in more than 90% of the cases, with hyperleukocytosis (у100 × 10 9 /l) in 64%. The t(4;11), or a variant, was found as the sole anomaly in 128 (70%) cases and together with additional changes in 55 (30%) ( Table 1 ). The frequencies of secondary changes differed, although not significantly, among the various age groups: 10/46 (22%) in patients below the age of 6 months, 3/17 (18%) in 6-11 months, 9/25 (36%) in 1-9 years old, 3/11 (27%) in 10-14 years, 2/5 (40%) in 15-19 years, 4/20 (20%) in 20-29 years, 7/17 (41%) in 30-39 years, 8/21 (38%) in 40-49 years, 5/15 (33%) in 50-59 years, and 4/6 (67%) in patients older than 60 years. The most frequent additional/secondary changes were gain of the X chromosome (10 females, 9 males), i(7)(q10), and trisomy 8 ( Table 2 ). An extra copy of the derivative chromosome 4 of the t(4;11) was seen in three cases, whereas no gains of the der(11) were detected. The breakpoint and imbalance maps (Figures 2 and 3 ) of the additional abnormalities reveal that chromosome bands 1p36, 1q21, 7q10, 11p15, 12p13, 17p11 and 17p10 are most frequently involved in structural rearrangements and that common imbalances include gains of 1q, 7q, 8, and X and losses of 7p and 17p. Five variant/complex t(4;11), all different, were found (Table 3) .
Information on survival could be ascertained in 171 patients (Table 4) . Kaplan-Meier estimates of event-free and overall survival (EFS and OS) showed no significant differences with Table 3 Variant/complex t(4;11) in the present series and in the literature Present series der(4)t(4;11)(q21;q23),der(11)del(11)(p?11p?15)t(4;11) t(1;4;11)(p36;q21;q23) der(2)t(2;11)(p21;p15),der(4)t(4;11)(q21;q23),der(11)t(2;11)t(4;11) der(3,4,11)t(3;11)(q29;q11)t(4;11)(q21;q23) t(1;4;11;12)(q21;q21;q23;q13) Literature data a ins(4;11)(q21;q11q23) t(4;11;19)(q21;q23;q13) t(4;11;13)(q21;q23;q14) der(4)t(?1;4)(?q21;q21),der(11)t(4;11)(q21;q23) der(4,11,15)t(4;15)(q11;q24)t(4;11)(q21;q23) der(4)t(1;11;4)(q21;q23q25;q21),der(11)t(4;11) t(4;11;12)(q21;q23;p13) t(4;11;17)(q21;q23;q11) t(4;11;15)(q21;q23;q21) ins(11;4)(q23;q21q31) t(4;6;11)(q21;p12;q23) a Cases ascertained from the Catalog of Chromosome Aberrations in Cancer. 5 regard to gender, WBC, or presence of secondary chromosomal abnormalities. Fifty-five patients had undergone bone marrow transplantation (BMT): 29 allogeneic (including eight from voluntary unrelated donors (VUD)), 22 autologous and four of unknown type. There was no significant difference in OS between those who had and had not been treated with BMT, whereas EFS was significantly shorter (P = 0.0247) in the BMT group compared to the non-BMT group (38 events in 55 BMT patients vs 40 events in 88 non-BMT patients), if early deaths (Ͻ90 days) and patients not achieving complete remission were excluded. When analyzing the various age groups separately, this difference in EFS was only seen in the Ͻ2 year group (P = 0.015). Age displayed an important prognostic impact, with significantly (P Ͻ 0.0001) longer EFS and OS in children 2-9 years old than among infants and younger children, patients aged between 10 and 39 years and older adults (Figure 4 ).
Discussion
The presenting features (Table 1 ) of the 183 t(4;11)-positive hematologic malignancies collected by the European 11q23 Workshop agree well with previous studies, ie young age at presentation, overrepresentation of females, hyperleukocytosis, bulky disease with relatively frequent involvement of the liver, spleen and lymph nodes, and pro-B ALL phenotype in most cases. 10, 11, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] The fact that six of the leukemias (3%) were morphologically classified as AML is also in line with what has been reported before. In fact, out of the 362 published cases with t(4;11), 11 (3%) have been AML, the majority AML-M4 and AML-M5. 5 The present finding of treatment-related leukemias in approximately 5% of the cases was also expected, although only a few studies have focused on therapy-associated ALL with 11q23/MLL rearrangements, as opposed to the well-known association between secondary AML and exposure to DNA topoisomerase II inhibitors. 56, 57 A review of the literature, however, reveals that all published therapy-associated t(4;11)-positive ALL, in which treatment was specified, had received chemotherapy targeting DNA topoisomerase II, ie etoposide, teniposide, doxorubicin, epidoxorubicin and mitoxantrone. 5 A detailed discussion on therapy-related 11q23 malignancies collected by the Workshop, including the present 10 cases, is found in Secker-Walker et al. 58 The majority of the 183 cases of leukemia displayed t(4;11) as the sole change; additional, or secondary, changes were seen in only 30% of the cases (Table 1 ). Previous studies have also shown that t(4;11) usually occurs as the sole anomaly. [28] [29] [30] [31] [32] 38, 59 Some variation in the frequency of secondary changes among the different age groups was noted, with a somewhat lower incidence (18-22%) in infants but the differences were not statistically significant. Pui, 59 on the other hand, reported that infants were significantly less likely to have additional abnormalities. These disparate results may well be due to the relatively low number of cases with secondary changes available for analysis (55 in the present study and 46 in the review by Pui). Since both studies indicate fewer AL with additional abnormalities in infants, further studies on the influence of age on secondary changes in t(4;11)-positive leukemias are definitely warranted.
Among the recurrent additional changes identified (Table 2) , gain of the X chromosome (equally common in females and males), i(7)(q10), and trisomy 8 were the most frequent. Although these aberrations have been noted in previous studies, [29] [30] [31] [32] 34, 35, 38, [59] [60] [61] the present compilation also demonstrated that the secondary rearrangements most often involved chromosome bands 1p36, 1q21, 7q10, 11p15, 12p13, 17p11, and 17p10 ( Figure 2 ) and that they led to frequent partial gains of 1q and 7q and partial losses of 7p and 17p (Figure 3) . In fact, all recurrent secondary aberrations were unbalanced, ie resulted in genomic imbalances (Table 2) , further strengthening the previously recognized general theme of such changes in acute leukemias, as well as in some solid tumor types, ie they are, for presently unknown reasons, almost always cytogenetically unbalanced. 62 The finding that only +der(4) occurred as an additional aberration, never +der(11), was somewhat unexpected, considering that it is the latter, ie the MLL/AF4 fusion, which, based on cytogenetic as well as molecular genetic studies, is suggested and believed to be the pathogenetically important outcome of the translocation. [18] [19] [20] [21] 23, 63, 64 The same pattern also emerged when reviewing all previously published t(4;11)-positive leukemias: +der(4), or +del(4)(q21), has been described in six cases, whereas +der(11) has never been reported. 5 Unless the +der(4) confers a selective advantage to the leukemic cells by increasing the amount of the reciprocal fusion transcript AF4/MLL, which we deem less likely, one has to conclude that gain of one or several other genes on
Figure 2
Breakpoint map of secondary structural chromosomal rearrangements in t(4;11)-positive acute leukemias, including also breakpoints in variant/complex translocations.
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Figure 3
Genomic imbalance map of secondary chromosomal abnormalities in t(4;11)-positive acute leukemias. Gains are indicated to the right, losses to the left side of each chromosome. OS, overall survival; EFS, event-free survival (patients who did not achieve complete remission are classed as having an event on day 1. One case had to be excluded due to lack of information as regards complete remission. Hence, the total number of 170 cases in the EFS analysis); CI, confidence intervals.
Figure 4
Kaplan-Meier estimates of EFS among cases with t(4;11), according to age.
4pter → cen → q21 is the essential consequence of the additional der(4). A further discussion on the occurrence of derivative chromosomes in 11q23-positive hematologic malignancies collected by the Workshop is found in Johansson et al. 65 Variant or complex t(4;11) were found in five (3%) of the 183 leukemias, an incidence well in accordance with previously published cases, where 11 out of 362 (3%) have had variant translocations (Table 3) . 5 None of these have been identical, but some breakpoints have been recurrently involved, ie 1q21, 11p15, and 11q11. Due to the low number of cases with variant/complex t(4;11) it is, at present, not possible to ascertain whether such cases are associated with any particular morphologic or clinical features. However, considering that variant translocations in other hematologic malignancies, such as in chronic myeloid leukemia, do not display a particular phenotypic impact, 7 it is reasonable to assume that the additional breakpoints also in t(4;11) variants are not associated with any morphologic or clinical characteristics. Obviously, further studies are warranted to test this assumption.
The apparent nonrandom pattern of the secondary changes in t(4;11) leukemias strongly suggests that they are pathogenetically important, most likely providing a selective advantage to the malignant clone during the leukemic evolution. If so, one would perhaps have expected that the additional abnormalities would have been of clinical importance, ie an ominous prognostic sign. However, the presence of secondary changes does not seem to have any prognostic impact, since there was no significant difference in EFS between cases with and without additional aberrations in the present study, and a similar conclusion was recently reached in a smaller series of t(4;11)-positive ALL. 61 This does not, however, imply that the additional aberrations do not confer any phenotypic t(4;11) in hematologic malignancies B Johansson et al 785 influence, ie that they would be neutral mutations. On the contrary, it is not unlikely that measuring the prognostic implications is a crude means of investigating the biologic impact of secondary changes, which may well affect quite discrete morphologic or immunophenotypic features that provide a selective advantage in a pretreatment environment but that are annihilated by the treatment. 62 A salient finding of the present study was the significant differences in EFS and OS among the various age groups, with a clearly better outcome in children 2-9 years old (Figure 4) . Although the therapy, for obvious reasons, was heterogeneous, it should be stressed that the vast majority of the patients had been treated with curative intent. In addition, this treatment heterogeneity is likely to apply to all age groups more or less equally. For these reasons we believe that the identified age differences in survival are likely to be valid and representative for t(4;11) leukemias in general. Furthermore, our finding that 2-9-year-old children had significantly longer EFS and OS than younger children and infants, adolescents and adults also agrees with the experience of Pui and coworkers. They initially reported that t(4;11) was a particularly adverse prognostic feature among infants and children above the age of 10 years, 38 and in a later update of their data children aged 1 to 9 years continued to have a better outcome than the other age groups. 66 They concluded that the dismal prognosis of adults, adolescents, and infants with t(4;11)-positive ALL would justify the use of BMT. In this regard, the present finding that BMT does not seem to prolong EFS or OS significantly is noteworthy and discouraging. However, further prospective, randomized studies are needed in order to substantiate and test this finding.
